Inovio Pharmaceuticals stock gains as analysts see sharp upside

Inovio Pharmaceuticals, Inc. stock (ISIN US45773H2013) is trading around 1.34 dollars on the Nasdaq as of September 2, 2026, with intraday data showing a price of 1.3401 dollars and a move of about 0.76 percent during the latest quoted session according to market data from Yahoo Finance as of early afternoon Eastern Time on that date.

Stock trades low versus analyst targets

According to market data compiled by Yahoo Finance as of September 2, 2026, Inovio Pharmaceuticals stock is quoted at roughly 1.34 dollars intraday, with recent Tradegate data translated from MarketScreener indicating a parallel quotation of about 1.152 euros for the secondary listing, highlighting the low absolute level of the share price in both USD and EUR terms.

Analyst consensus compiled by Zacks as of a recent update shows that short term price targets from six covering analysts average 7.50 dollars per share, compared with a last closing price of 1.33 dollars at the time of that compilation, which implies an upside of about 463.91 percent from that closing level if the average target were reached, underscoring how far the current market price still stands below the analyst expectations in percentage terms.

Volatility and performance on Tradegate

Tradegate quotation data reported by MarketScreener as of September 2, 2026 indicate that Inovio Pharmaceuticals stock recently closed around 1.152 euros on that venue, with a five day change of about plus 5.79 percent and a year to date change in the range of negative low double digits, illustrating a mix of short term recovery and longer term pressure for the shares in the German market.

The same data set shows that the year to date performance of Inovio Pharmaceuticals stock on Tradegate has been around minus twenty percent in euro terms depending on the specific snapshot, which puts the stock clearly below the level at the start of the year and helps investors gauge the distance that would need to be recovered before the pre year level is reached again.

DNA medicines pipeline as business driver

Inovio Pharmaceuticals, Inc. is described in company and market profiles, including MarketScreener, as a biotechnology company focused on developing and commercializing deoxyribonucleic acid medicines designed to help treat and protect people from human papillomavirus related diseases, cancer and various infectious diseases, positioning the business in the field of immuno oncology and infectious disease vaccines and therapies.

The companys pipeline spans therapeutic and preventive candidates that use DNA plasmids delivered into cells to trigger immune responses, an approach that has attracted attention during recent years for potential applications in areas such as HPV related precancerous lesions and certain viral infections, and that continues to underpin investor interest in the stock despite the currently low market valuation relative to analyst projections.

Stock and valuation snapshot

As of September 2, 2026, intraday data from Yahoo Finance indicate that Inovio Pharmaceuticals stock trades around 1.3401 dollars with a modest positive intraday change of about 0.76 percent, while earlier same day commentary on StockTitan referred to a last price of about 1.40 dollars and a percent move in the mid single digits range, which signals that the stock can fluctuate materially even within a single trading session.

At these price levels, the market capitalization of Inovio Pharmaceuticals, Inc. remains in the small cap range within the biotechnology sector, and the gap between the present share price near 1.34 dollars and the average analyst target of 7.50 dollars quantified by Zacks translates into a multiple of more than five times the current price, a ratio that many investors will view as both an indicator of perceived upside potential and a reminder of the significant risk inherent in such speculative biotechnology names.

Inovio Pharmaceuticals key data

• Company: Inovio Pharmaceuticals, Inc.
• ISIN: US45773H2013
• Ticker: INO
• Trading venue: Nasdaq, Tradegate secondary listing
• Price (as of September 2, 2026): 1.3401 USD
• Market capitalization: Small cap biotechnology, USD based (as of September 2, 2026)
• Sector / Industry: Biotechnology, pharmaceuticals
• Index membership: Not a member of major large cap indices such as S&P 500